Why Affordable Insulin Is a Money Problem, Not a Science Problem – Part 2
What happens when the solution to America’s insulin crisis isn’t a new molecule or fancy delivery device—but a new way of thinking about biotech itself?
Why Affordable Insulin Is a Money Problem, Not a Science Problem – Part 1
What if affordable insulin isn’t a scientific hurdle—but a financial and distribution puzzle no one’s been motivated to solve?
Why Strong Science Isn’t Enough to Get Funded: What Investors Actually Look For – Part 2
Securing capital for biotech innovation has never been more challenging—or more crucial.
Why Strong Science Isn’t Enough to Get Funded: What Investors Actually Look For – Part 1
Strong science alone won’t get your biotech startup funded—investors are sizing up much more than just your molecule.